Juno Therapeutics Inc (JUNO) : Sib added new position in Juno Therapeutics Inc during the most recent quarter end. The investment management firm now holds 100,000 shares of Juno Therapeutics Inc which is valued at $2,917,000 , the company said in a statement filed on Oct 7, 2016 with the SEC.Juno Therapeutics Inc makes up approximately 2.37% of Sib’s portfolio.
Other Hedge Funds, Including , Simplex Trading reduced its stake in JUNO by selling 14,311 shares or 46.42% in the most recent quarter. The Hedge Fund company now holds 16,520 shares of JUNO which is valued at $481,888. Juno Therapeutics Inc makes up approx 0.06% of Simplex Trading’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in JUNO in the latest quarter, The investment management firm added 7,526 additional shares and now holds a total of 22,204 shares of Juno Therapeutics Inc which is valued at $658,349.Private Asset Management Inc boosted its stake in JUNO in the latest quarter, The investment management firm added 57,600 additional shares and now holds a total of 63,975 shares of Juno Therapeutics Inc which is valued at $1,896,859. Juno Therapeutics Inc makes up approx 0.32% of Private Asset Management Inc’s portfolio. Washington Trust Bank added JUNO to its portfolio by purchasing 11 company shares during the most recent quarter which is valued at $326.
Juno Therapeutics Inc opened for trading at $28.95 and hit $29.55 on the upside on Friday, eventually ending the session at $29.17, with a gain of 0.79% or 0.23 points. The heightened volatility saw the trading volume jump to 10,93,778 shares. Company has a market cap of $3,086 M.
On the company’s financial health, Juno Therapeutics Inc reported $-0.64 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.59. The company had revenue of $27.60 million for the quarter, compared to analysts expectations of $9.80 million. The company’s revenue was up 121.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.35 EPS.
Many Wall Street Analysts have commented on Juno Therapeutics Inc. Shares were Reiterated by Maxim Group on Aug 5, 2016 to “Buy” and Lowered the Price Target to $ 50 from a previous price target of $80 .
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.